Immunogen Inc., of Waltham, Mass., reported a net loss, for the fiscal year ended June 30, 2013, of $72.8 million, or $0.87 per basic and diluted share, compared to a net loss of $73.3 million, or $0.95 per basic and diluted share, for the comparable period last year. For the quarter, the company reported a net loss of $21.9 million, or $0.26 per basic and diluted share, compared to a net loss of $22.4 million, or $0.29 per basic and diluted share, for the same quarter in 2012. Revenues in FY2013 were $35.5 million, which included $24.2 million of license and milestone fees from a $10.5 million milestone payment from Roche earned with the approval in February of Kadcyla (trastuzumab emtansine, Roche AG) for HER2 breast cancer in the U.S. and $11.1 million of amortization of up-front license fees received from Novartis AG. The company had approximately $195 million in cash as of June 30, 2013, compared with $160.9 million as of June 30, 2012, and had no debt outstanding in either period.